

# Ippazio Cosimo Antonazzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1459465/publications.pdf>

Version: 2024-02-01

29  
papers

404  
citations

932766

10  
h-index

794141

19  
g-index

29  
all docs

29  
docs citations

29  
times ranked

563  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 205-214.	1.0	4
2	Overview of the <sc>European postâ€ authorization study</sc> register postâ€ authorization studies performed in Europe from September 2010 to December 2018. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 689-705.	0.9	9
3	Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 178.	1.1	8
4	Haemophilia management and treatment: An Italian survey on patientsâ€™, caregiversâ€™ and cliniciansâ€™ point of view. <i>Haemophilia</i> , 2022, 28, 254-263.	1.0	5
5	Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy. <i>PLoS ONE</i> , 2022, 17, e0264123.	1.1	2
6	The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. <i>Archives of Public Health</i> , 2022, 80, 142.	1.0	9
7	Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973). <i>Journal of Clinical Medicine</i> , 2022, 11, 3434.	1.0	1
8	Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e120-e120.	0.5	15
9	Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 983-989.	0.8	29
10	Assessment of adverse reactions to Î±-lipoic acid containing dietary supplements through spontaneous reporting systems. <i>Clinical Nutrition</i> , 2021, 40, 1176-1185.	2.3	18
11	Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women. <i>Atherosclerosis</i> , 2021, 317, 59-66.	0.4	6
12	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. <i>Neuroepidemiology</i> , 2021, 55, 224-231.	1.1	4
13	COVID-19 Outbreak Impact on Anticoagulants Utilization: An Interrupted Time-Series Analysis Using Health Care Administrative Databases. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1115-1118.	1.8	3
14	Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Emergency Department Access in People with Epilepsy: An Interrupted Time-Series Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13253.	1.2	8
15	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drugâ€ drug interactions through the FDA adverse event reporting system. <i>Acta Diabetologica</i> , 2020, 57, 71-80.	1.2	18
16	Signal of potentially protective drugâ€ drug interactions from spontaneous reporting systems: proceed with caution. <i>Acta Diabetologica</i> , 2020, 57, 115-116.	1.2	4
17	Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region. <i>Frontiers in Pharmacology</i> , 2020, 11, 624888.	1.6	12
18	<p>Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1157-1170.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements. <i>Clinical Nutrition</i> , 2020, 39, 3854-3855.	2.3	1
20	Drug-induced Kounis syndrome: A matter of pharmacovigilance. <i>International Journal of Cardiology</i> , 2019, 274, 381.	0.8	9
21	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	1.7	72
22	Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. <i>PLoS ONE</i> , 2019, 14, e0211938.	1.1	3
23	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. <i>Oncologist</i> , 2019, 24, e1228-e1231.	1.9	30
24	Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1633-1640.	1.4	21
25	Hepatitis B vaccination and the putative risk of central demyelinating diseases – A systematic review and meta-analysis. <i>Vaccine</i> , 2018, 36, 1548-1555.	1.7	37
26	Human papillomavirus vaccine and demyelinating diseases – A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2018, 132, 108-118.	3.1	32
27	Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 869-874.	1.0	10
28	The Burden of Chronic Heart Failure in Primary Care in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 171-178.	1.0	16
29	Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. <i>Drug Safety</i> , 2017, 40, 823-834.	1.4	6